Edge Therapeutics To Discontinue NEWTON 2 Study - Quick Facts

(RTTNews) - Edge Therapeutics, Inc. (EDGE) announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study's primary endpoint, if the study is fully enrolled. Based on the recommendation of The independent Data Monitoring Committee, Edge has decided to discontinue the NEWTON 2 study as it has a low probability of meeting the primary endpoint.

Edge said it will assess the next steps for the company, but anticipates in the near term reducing the scope of its operations, including the size of its workforce, in order to preserve its cash resources, which were $88.1 million as of December 31, 2017.